Investigation Of Several Methods Related To Preclinical Diabetic Nephropathy Studies And Ameliorative Effects Of Some Agents On Diabetic Nephropathy In Animals

About 40% diabetic patients develop kidney complications eventually. Diabetic nephropathy is a leading cause of end-stage renal failure, accounting for 35% to 40% of all new cases requiring dialysis therapy throughout the world. Preclinical study is very important for finding new drugs to treat, diabetic nephropathy. In this study several methods very useful to preclinical study of diabetic nephropathy were developed and the ameliorative effects of several agents on diabetic nephropathy in rat and mouse diabetic models were observed.Part I A competitive ELISA for albumin in rat urine (attached: a competitive ELISA for albumin in mouse urine)Nephropathy is characterized by urinary micro-albumin. Rat is usually used in experimental studies. But there was no specific and simple method for detecting rat urinary albumin. A specific, easily operated and sensitive method for quantitatively determining rat urinary albumin is needed. Using rabbit anti-rat albumin polyclonal antibody, a competitive ELISA for rat albumin in urine was developed. With this method the urinary albumin in diabetic and normal rats was detected. The rabbit anti-rat albumin polyclonal antibody showed no cross reaction with bovine, human serum albumin and rat IgG. Based on the cross-reaction of the rabbit anti-rat albumin antibody with mouse albumin, a competitive ELISA for mouse urinary albumin was also established. The urinary albumin markedly increased in diabetic rats and mice.Part II Development and application of the ELISA method for measuring...